Načítá se...
Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes
Myelodysplastic syndromes (MDS) represent a heterogeneous group of acquired clonal hematopoietic disorders characterized by peripheral blood cytopenias, paradoxical BM hypercellularity, ineffective hematopoiesis, and increased risk of leukemic transformation. Risk stratification, using different pro...
Uloženo v:
| Vydáno v: | J Blood Med |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4278786/ https://ncbi.nlm.nih.gov/pubmed/25565910 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JBM.S50482 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|